Sanofi beat sales and adjusted profit-per-share forecasts and raised its 2026 sales forecast as Dupixent sales surged. Vaccine sales fell, and Dupixent will eventually face competition, but the strong results and higher forecast point upward.
Dupixent is driving much of the growth. Vaccine sales fell, and Sanofi is preparing for Dupixent to face competition after its exclusivity ends. The strong results and higher company forecast give the better reading.
Follow Sanofi (SNY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SNY